Juan Jose Toro1, Francisca Cecilia Gushiken2, Deanna Schneider2, Shuko Lee2, David Johannes Haile2, Cesar Ovidio Freytes2. 1. Audie L. Murphy Memorial Veterans Hospital, South Texas Veterans Health Care System, 7400 Merton Minter Blvd., San Antonio, TX, 78229, USA. Juan.toro2@va.gov. 2. Audie L. Murphy Memorial Veterans Hospital, South Texas Veterans Health Care System, 7400 Merton Minter Blvd., San Antonio, TX, 78229, USA.
Abstract
PURPOSE: Patients undergoing autologous hematopoietic stem cell transplantation (HSCT) are at risk for oral complications which may cause significant morbidity. The aim of this study was to compare the incidence of toxicities and complications in edentulous and dentate patients undergoing autologous HSCT for multiple myeloma. METHODS: We conducted a retrospective case-control study to analyze the incidence of bacteremia, fever, and oral mucositis, between edentulous and dentate patients. All patients underwent dental evaluation, received dental treatment if indicated, and were cleared before transplantation. The two groups were matched for age, gender, ethnicity, disease stage, time from diagnosis to transplant, performance status, and conditioning regimen. RESULTS: A total of 45 edentulous and 90 dentate patients were enrolled. All patients were male with a median age of 60 years and a mean performance status by Karnofsky score of 90 %. Two thirds had stage III MM with a median time from diagnosis to transplantation of 12 months, and all received melphalan as part of the conditioning regimen. The incidence of bacteremia (p = 0.553), fever (p = 0.245), severity of oral mucositis (p = 0.465), and other post-transplant toxicities were similar between both groups. CONCLUSIONS: There were no significant differences in the incidence of bacteremia, fever, severity of oral mucositis, or other complications between edentulous and dentate patients with multiple myeloma after autologous HSCT.
PURPOSE:Patients undergoing autologous hematopoietic stem cell transplantation (HSCT) are at risk for oral complications which may cause significant morbidity. The aim of this study was to compare the incidence of toxicities and complications in edentulous and dentate patients undergoing autologous HSCT for multiple myeloma. METHODS: We conducted a retrospective case-control study to analyze the incidence of bacteremia, fever, and oral mucositis, between edentulous and dentate patients. All patients underwent dental evaluation, received dental treatment if indicated, and were cleared before transplantation. The two groups were matched for age, gender, ethnicity, disease stage, time from diagnosis to transplant, performance status, and conditioning regimen. RESULTS: A total of 45 edentulous and 90 dentate patients were enrolled. All patients were male with a median age of 60 years and a mean performance status by Karnofsky score of 90 %. Two thirds had stage III MM with a median time from diagnosis to transplantation of 12 months, and all received melphalan as part of the conditioning regimen. The incidence of bacteremia (p = 0.553), fever (p = 0.245), severity of oral mucositis (p = 0.465), and other post-transplant toxicities were similar between both groups. CONCLUSIONS: There were no significant differences in the incidence of bacteremia, fever, severity of oral mucositis, or other complications between edentulous and dentate patients with multiple myeloma after autologous HSCT.
Authors: Christa E Nath; Peter J Shaw; Judith Trotman; Lihua Zeng; Stephen B Duffull; Gareth Hegarty; Andrew J McLachlan; Howard Gurney; Ian Kerridge; Yiu Lam Kwan; Peter Presgrave; Campbell Tiley; Douglas Joshua; John Earl Journal: Br J Clin Pharmacol Date: 2010-05 Impact factor: 4.335
Authors: M L Grazziutti; L Dong; M H Miceli; S G Krishna; E Kiwan; N Syed; A Fassas; F van Rhee; H Klaus; B Barlogie; E J Anaissie Journal: Bone Marrow Transplant Date: 2006-10 Impact factor: 5.483
Authors: M A Reynolds; G E Minah; D E Peterson; D S Weikel; L T Williams; C D Overholser; L G DePaola; J B Suzuki Journal: J Clin Periodontol Date: 1989-03 Impact factor: 8.728
Authors: Ulas D Bayraktar; Qaiser Bashir; Muzaffar Qazilbash; Richard E Champlin; Stefan O Ciurea Journal: Biol Blood Marrow Transplant Date: 2012-08-24 Impact factor: 5.742